<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031991</url>
  </required_header>
  <id_info>
    <org_study_id>B7391001</org_study_id>
    <secondary_id>REFLECTIONS B739-01</secondary_id>
    <nct_id>NCT02031991</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)</brief_title>
  <official_title>Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to prove that the handling (also referred to as pharmacokinetics) of the
      following drugs PF-06439535, Avastin® (bevacizumab) that is licensed for use in the United
      States (bevacizumab-US) and Avastin® (bevacizumab) obtained from Europe (bevacizumab-EU) is
      similar in healthy male volunteers after receiving a single intravenous dose of either drugs.

      During the course of the study, the similarity in pharmacokinetics will be assessed by
      sampling the levels of drug in the blood, and by comparing these levels among the different
      administration arms of PF-06439535, bevacizumab-US and bevacizumab-EU. Safety, tolerability,
      and immunologic response to the administered drugs will also be evaluated throughout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]</measure>
    <time_frame>Day 1 - Day 71</time_frame>
    <description>AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Disposition Half-Life (t1/2)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab)</measure>
    <time_frame>Day 1 - Day 71 or LSLV, whichever occurs later</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A = PF-06439535</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B = Bevacizumab-EU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C = Bevacizumab-US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06439535</intervention_name>
    <description>Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.</description>
    <arm_group_label>A = PF-06439535</arm_group_label>
    <other_name>PF-06439535, a potential biosimilar to bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.</description>
    <arm_group_label>B = Bevacizumab-EU</arm_group_label>
    <other_name>Bevacizumab (European Union)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.</description>
    <arm_group_label>C = Bevacizumab-US</arm_group_label>
    <other_name>Bevacizumab (United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects 21-55 years old

          -  Subjects who have previously been exposed to a biologic agent (other than a VEGF
             [Vascular Endothelial Growth Factor Receptor] inhibitor) may enroll provided that at
             least 3 months have passed since the last administration of that drug

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50kg (110lbs)

        Exclusion Criteria:

          -  Evidence or history of a clinically significant disease or clinical finding at
             Screening

          -  Previous treatment with an anti-VEGF antibody, or any other antibody or protein
             targeting the VEGF receptor.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7391001&amp;StudyName=A%20Pharmacokinetic%20Study%20Comparing%20PF-06439535%20And%20Bevacizumab%20In%20Healthy%20Male%20Volunteers%20%28REFLECTIONS%20B739-01%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>August 14, 2014</last_update_submitted>
  <last_update_submitted_qc>August 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Biosimilarity</keyword>
  <keyword>Similarity</keyword>
  <keyword>PK</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Single-Dose</keyword>
  <keyword>Oncology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

